.jpg?format=webp&width=780)
The study aimed to compare the risk of benign prostatic hyperplasia (BPH)-related surgery and acute urinary retention (AUR) in men treated with 5-alpha-reductase inhibitor (5-ARI) versus alpha-blocker monotherapy in routine clinical care over 15 years of follow-up. The study included 18,421 men treated with 5-ARI and 95,984 men treated with alpha-blockers. The results showed that treatment with 5-ARI was associated with a reduced risk of BPH-related surgery and AUR compared to alpha-blocker monotherapy, with a relative risk reduction of 21-25% and an absolute risk reduction of 4% after 15 years of follow-up.
Like
Save
Share